PET Response-adapted Therapy in Advanced-stage Hodgkin Lymphoma Appears Beneficial
Patients with advanced-stage Hodgkin lymphoma who were at high risk for treatment failure as determined by interim PET response.
Diagnosis & Disease Information
VEPEMB Compared With ABVD for Older Patients With Hodgkin Lymphoma
Standard ABVD was associated with a significant improvement in survival in older patients with Hodgkin lymphoma.
Treatment Disparity Identified in HIV-positive Black Patients With Hodgkin Lymphoma
Significant disparities have been found in HIV-positive black patients with Hodgkin lymphoma, with regard to both rate of diagnosis and chemotherapy usage.
ABVD Shows Higher Progression-free Survival in Hodgkin Lymphoma
Patients with advanced Hodgkin lymphoma treated with BEACOPP or CEC did not show a progression-free survival.
We Can Treat Hodgkin’s Lymphoma Like Melanoma?
Isabel Cunningham, MD, Cancer Therapy Advisor Advisory Board member, weighs in on recent discoveries in the treatment of hematologic cancers.
In Stage 1A Hodgkin Lymphoma, Involved-field Radiotherapy Should Be Standard of Care
Involved-field radiotherapy (IF-RT) should be considered standard of care for stage 1A nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL).
Evaluating Evolution of Incidence Rates of Hodgkin Lymphoma Subtypes
Recent declines in nodular sclerosis (NS) rates represented true incidence changes in Hodgkin lymphoma (HL).
Higher Survival with Brentuximab Vedotin After Stem Cell Transplant
For Hodgkin’s lymphoma, brentuximab vedotin is associated with improved progression-free survival after autologous stem-cell transplant.
PET-Adapted Salvage Therapy Achieves Negativity in Hodgkin Lymphoma
PET-adapted sequential salvage therapy with brentuximab could optimize chance of cure in relapsed and refractory Hodgkin lymphoma.
Socioeconomic Factors Affect Treatment Selection, Outcomes in Early-Stage Hodgkin Lymphoma
Socioeconomic factors affect selection of curative treatments in Hodgkin lymphoma.
- Loading...
Loading...
Loading... 
Loading...